

Human VEGF-A ELISA Kit

Instructions for use

Catalogue numbers:	1x48 tests:	650.080.048
	1x96 tests:	650.080.096
	2x96 tests:	650.080.192

For research use only

Fast Track Your Research.....

Table of Contents

1.	Intended Use.....	2
2.	Introduction	2
2.1.	Summary.....	2
2.2.	Principle of The Method.....	3
3.	Reagents Provided And Reconstitution	3
4.	Materials Required But Not Provided.....	3
5.	Storage Instructions.....	4
6.	Specimen Collection, Processing & Storage	4
7.	Safety & Precautions For Use	5
8.	Assay Preparation	6
8.1.	Assay Design	6
8.2.	Preparation of Wash Buffer.....	6
8.3.	Preparation of Assay Buffer	6
8.4.	Preparation of Standard.....	7
8.5.	Preparation of Biotin-Conjugate.....	7
8.6.	Preparation of Streptavidin-HRP	7
9.	Method	8
10.	Data Analysis	9
11.	Assay Limitations	9
12.	Performance Characteristics	10
12.1.	Sensitivity.....	10
12.2.	Specificity.....	10
12.3.	Precision.....	10
12.4.	Dilution Parallelism.....	10
12.5.	Spike Recovery.....	10
12.6.	Stability.....	11
12.7.	Expected Serum Values	11
13.	Bibliography.....	12
14.	Assay Summary.....	13

Human VEGF-A ELISA KIT

1. Intended use

The Diaclone VEGF-A ELISA kit is a solid phase sandwich ELISA for the *in-vitro* qualitative and quantitative determination of VEGF-A in supernatants, buffered solutions or serum and plasma samples. This assay will recognise both natural and recombinant human VEGF-A.

This kit has been configured for research use only. Not suitable for use in therapeutic procedures.

2. Introduction

2.1. Summary

Normal tissue function depends on a regular supply of oxygen through the blood vessels. Understanding the formation of blood vessels has become the focus of a major research effort throughout the last decade. Vasculogenesis in the embryo is the process by which new blood vessels are generated *de novo* from primitive precursor cells. Angiogenesis is the process of new blood vessel formation from pre-existing vasculatures. It plays an essential role in development, normal tissue growth, wound healing, the female reproductive cycle (placental development, ovulation, corpus luteum) and also plays a major role in various diseases (1). Special interest is focused on tumor growth, since tumors cannot grow more than a few millimeters in size without developing a new blood supply. This process is described as tumor angiogenesis which is also essential for the spread and growth of tumor cell metastasis. One of the key molecules for angiogenesis and for the survival of the endothelium is vascular endothelial growth factor (VEGF-A) (2). It is a specific endothelial cell mitogen and a strong vascular permeability factor (VPF) (3). VEGF-A is a heparin-binding glycoprotein, secreted as a homodimer of 45 kDa by many different cell types. VEGF-A also causes vasodilation through the nitric oxide synthase pathway in endothelial cells and can activate migration in monocytes. Many different splice variants of VEGF-A have been described, but VEGF₁₆₅ is the most predominant protein and anchors with its heparin binding domain to extracellular matrix and to heparin sulfate. During the past few years, several other members of the VEGF family have been cloned, including VEGF-B, -C- and -D. In terms of vascular angiogenesis, which mainly is regulated by VEGF-A, lymphangiogenesis is mainly regulated by VEGF-C and -D (4).

VEGF-A transcription is highly activated by hypoxia and by oncogenes (5) like H-ras and several transmembrane tyrosine kinases, such as epidermal growth factor receptor and ErbB2 (6). Together these pathways account for a marked upregulation of VEGF-A in tumors compared to normal tissues and are often of prognostic importance and relevance (7,8). VEGF-A can be detected in both plasma and serum samples of patients, with much higher levels in serum (9). Extremely high levels can be detected in the cystic brain fluid of brain tumor patients (10,11) or in ascites fluid of patients. Platelets release VEGF-A upon aggregation and may be another major source of VEGF-A delivery to tumors (12). Several other studies have shown that association of high serum levels of VEGF-A with poor prognosis in cancer patients may be correlated with an elevated platelet count (13). Tumors can release cytokines and growth factors that stimulate the production of megakaryocytes in the marrow and elevate the platelet count. This can result in another, indirect increase of VEGF-A delivery to tumors (14). Furthermore, VEGF-A is implicated in several other pathological conditions associated with enhanced angiogenesis or enhanced vascular permeability. Examples where VEGF-A plays an important role are psoriasis and rheumatoid arthritis (15), as well as the ovarian hyperstimulation syndrome (16). Diabetic retinopathy is associated with high intraocular levels of VEGF-A, and inhibition of VEGF-A function may result in infertility by blockage of corpus luteum function (17). Direct demonstration of the importance of VEGF-A in tumor growth has been achieved using dominant negative VEGF receptors to block *in vivo* proliferation (18), as well as blocking antibodies to VEGF or to one of the VEGF receptors (19). Interference with VEGF-A function has therefore become of major interest for drug development to block angiogenesis and metastasis. More than 110 pharmaceutical companies world-wide are involved in the development of such antagonists. Their approaches include antagonists of VEGF-A or its receptors, selective tyrosine kinase inhibitors, targeting of drugs and toxins to VEGF receptors and gene therapy regulated by the same hypoxia pathway that controls VEGF-A production, Targeting the VEGF signalling may be of major therapeutic importance for many diseases (20) and serves as a basis for the design of future (anti)-angiogenic treatments.

2.2. Principle of the method

The VEGF-A kit is a solid phase sandwich Enzyme Linked-Immuno- Sorbent Assay (ELISA). A monoclonal antibody specific for VEGF-A has been coated onto the wells of the microtiter strips provided. Samples, including standards of known VEGF-A concentrations and unknowns are pipetted into these wells.

During the first incubation, the VEGF-A antigen is added to wells. After washing, a biotinylated monoclonal antibody specific for VEGF-A is incubated. Then the enzyme (streptavidin-peroxydase) is added. After incubation and washing to remove all unbound enzyme, a substrate solution which acts on the bound enzyme is added to induce a coloured reaction product. The intensity of this coloured product is directly proportional to the concentration of VEGF-A present in the samples.

3. Reagents provided and reconstitution

Reagents (Store@2-8°C)	Quantity 1x96 well kit Cat no. 650.080.096	Quantity 2x96 well kit Cat no. 650.080.192	Reconstitution
Coated Plate anti VEGF-A	1	2	Ready to use (96 well strip pre-coated plate)
Plastic plate covers	2	4	n/a
VEGF-A Standard: 2 ng/ml	2	4	Reconstitute as directed on the vial (see Assay preparation, section 8)
Assay Buffer	1 (5ml)	2 (5ml)	20x Concentrate, dilute in distilled water (see Assay preparation, section 8)
Biotin-Conjugate anti VEGF-A	1 (120µl)	2 (120µl)	Dilute in Assay Buffer 1X (see Assay preparation, section 8)
Sample Diluent	1 (12ml)	2 (12ml)	Ready to use
Streptavidin-HRP	1 (150µl)	2 (150µl)	Dilute in Assay Buffer 1X (see Assay preparation, section 8)
Wash Buffer	1 (50ml)	2 (50ml)	20x Concentrate, dilute in distilled water (see Assay preparation, section 8)
Substrate Solution	1 (15ml)	2 (15ml)	Ready to use
Stop Solution	1 (15ml)	2 (15ml)	Ready to use

4. Materials required but not provided

- Microtiter plate reader fitted with appropriate filters (450 nm required with optional 620 nm reference filter)
- Microplate washer or wash bottle
- 10, 50, 100, 200 and 1,000µl adjustable single channel micropipettes with disposable tips
- 50-300µl multi-channel micropipette with disposable tips
- Multichannel micropipette reagent reservoirs
- Distilled water
- Vortex mixer
- Miscellaneous laboratory plastic and/or glass, if possible sterile

5. Storage Instructions

Store kit reagents between 2 and 8°C. Immediately after use remaining reagents should be returned to cold storage (2-8°C). Expiry of the kit and reagents is stated on box front labels. The expiry of the kit components can only be guaranteed if the components are stored properly, and if, in case of repeated use of one component, the reagent is not contaminated by the first handling.

Wash Buffer 1X: Once prepared, store at 2-8°C for up to 30 days.

Assay Buffer 1X: Once prepared, store at 2-8°C for up to 30 days.

Reconstituted Standard: Once prepared use immediately and do not store.

Diluted Biotin-Conjugate: Once prepared use immediately and do not store.

Diluted Streptavidin-HRP: Once prepared use immediately and do not store.

6. Specimen collection, processing & storage

Cell culture supernatants, human serum and plasma (EDTA, Citrate, heparin) were tested with this assay. Other biological samples might be suitable for use in the assay. Remove serum from the clot or red cells, respectively, as soon as possible after clotting and separation.

Pay attention to possibly elevated serum level of human VEGF-A due to VEGF-A release by platelets during platelet activation (sampling process).

Cell culture supernatants: Remove particulates and aggregates by spinning at approximately 1000 x g for 10 min.

Serum: Use pyrogen/endotoxin free collecting tubes. Serum should be removed rapidly and carefully from the red cells after clotting. Following clotting, centrifuge at approximately 1000 x g for 10 min and remove serum.

Plasma: EDTA, citrate and heparin plasma can be assayed. Spin samples at 1000 x g for 30 min to remove particulates. Harvest plasma.

Storage: If not analyzed shortly after collection, samples should be aliquoted (250-500µl) to avoid repeated freeze-thaw cycles and stored frozen at -70°C. Avoid multiple freeze-thaw cycles of frozen specimens.

Recommendation: Do not thaw by heating at 37°C or 56°C. Thaw at room temperature and make sure that sample is completely thawed and homogeneous before use. When possible avoid use of badly haemolysed or lipemic sera. If large amounts of particles are present these should be removed prior to use by centrifugation or filtration.

7. Safety & precautions for use

- Handling of reagents, serum or plasma specimens should be in accordance with local safety procedures, e.g. CDC/NIH Health manual : "Biosafety in Microbiological and Biomedical Laboratories" 1984.
- Laboratory gloves should be worn at all times.
- Avoid any skin contact with Stop Solution and Substrate Solution. In case of contact, wash thoroughly with water.
- Do not eat, drink, smoke or apply cosmetics where kit reagents are used.
- Do not pipette by mouth.
- When not in use, kit components should be stored refrigerated as indicated on vials or bottles labels.
- All reagents should be warmed to room temperature before use. Lyophilized standards should be discarded after use.
- Once the desired number of strips has been removed, immediately reseal the bag to protect the remaining strips from deterioration.
- Cover or cap all reagents when not in use.
- Do not mix or interchange reagents between different lots.
- Do not use reagents beyond the expiration date of the kit.
- Use a clean disposable plastic pipette tip for each reagent, standard, or specimen addition in order to avoid cross contamination, for the dispensing of Stop solution and Substrate Solution, avoid pipettes with metal parts.
- Use a clean plastic container to prepare the washing solution.
- Thoroughly mix the reagents and samples before use by agitation or swirling.
- All residual washing liquid must be drained from the wells by efficient aspiration or by decantation followed by tapping the plate forcefully on absorbent paper. Never insert absorbent paper directly into the wells.
- The Substrate Solution is light sensitive. Avoid prolonged exposure to light. Also, avoid contact of the Substrate Solution with metal to prevent colour development. Warning Substrat is toxic avoid direct contact with hands. Dispose off properly.
- If a dark blue colour develops within a few minutes after preparation, this indicates that the Substrate Solution has been contaminated and must be discarded. Read absorbance's within 1 hour after completion of the assay.
- When pipetting reagents, maintain a consistent order of addition from well-to-well. This will ensure equal incubation times for all wells.
- Follow incubation times described in the assay procedure.
- Dispense the Substrate Solution within 15 min of the washing of the microtiter plate.

8. Assay Preparation

Bring all reagents to room temperature before use

8.1. Assay Design

Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running zeros and standards. Each sample, standard and Blank should be tested **in duplicate**. Remove sufficient microwell strips for testing from the pouch immediately prior to use. Return any wells not required for this assay with desiccant to the pouch. Seal tightly and return to 2-8°C storage.

Example plate layout (example shown for a 6 point standard curve)

	Standards		Sample Wells									
	1	2	3	4	5	6	7	8	9	10	11	12
A	Std 1	Std 1										
B	Std 2	Std 2										
C	Std 3	Std 3										
D	Std 4	Std 4										
E	Std 5	Std 5										
F	Std 6	Std 6										
G	Blank	blank										
H												

All remaining empty wells can be used to test samples in duplicate

8.2. Preparation of Wash Buffer

If crystals have formed in the Wash Buffer Concentrate, warm it gently until they have completely dissolved.

Pour entire contents (50 ml) of the **Wash Buffer Concentrate** into a clean 1,000 ml graduated cylinder. Bring final volume to 1,000 ml with glass-distilled or deionized water. Mix gently to avoid foaming. The pH of the final solution should adjust to 7.4.

Transfer to a clean wash bottle and store at 2° to 25°C.

8.3. Preparation of Assay Buffer 1X

Mix the contents of the bottle well. Add contents of **Assay Buffer Concentrate** (5.0 ml) to 95 ml distilled or deionized water and mix gently to avoid foaming. Store at 2° to 8°C.

8.4. Preparation of Standard

Standard vials must be reconstituted with the volume of distilled water shown on the vial immediately prior to use. This reconstitution gives a stock solution of 2 ng/ml of VEGF-A. Mix the reconstituted standard gently by inversion only. Serial dilutions of the standard are made directly in the assay plate to provide the concentration range from 1000 to 31.25 pg/ml. A fresh standard curve should be produced for each new assay.

- Add 100µl of Sample Diluent to all standard and blank wells.
- Immediately after reconstitution add 100µl of the reconstituted standard to wells A1 and A2, which provides the highest concentration standard at 1000pg/ml. Mix the well contents by repeated aspirations and ejections taking care not to scratch the inner surface of the wells.
- Transfer 100µl from wells A1 and A2 to B1 and B2. Mix the well contents by repeated aspirations and ejections taking care not to scratch the inner surface of the wells.
- Continue this 1:1 dilution using 100µl from wells B1 and B2 through to wells F1 and F2 providing a serial diluted standard curve ranging from 1000 to 31.25pg/ml
- Discard 100µl from the final wells of the standard curve (F1 and F2)

Alternatively these dilutions can be performed in separate clean tubes and immediately transferred into the relevant wells.

8.5. Preparation of Biotin-Conjugate

Make a 1:100 dilution with Assay Buffer 1X in a clean plastic tube as needed according to the following table:

Number of Strips	Biotin-Conjugate (µl)	Assay Buffer 1X (ml)
1 - 6	60	5.94
1 - 12	120	11.88

8.6. Preparation of Streptavidin-HRP

Make a 1:100 dilution of the concentrated Streptavidin-HRP solution in Assay Buffer 1X as needed according to the following table:

Number of Strips	Streptavidin-HRP (µl)	Assay Buffer 1X (ml)
1 - 6	60	5.94
1 - 12	120	11.88

9. Method

We strongly recommend that every vial is mixed thoroughly without foaming prior to use.

Prepare all reagents as shown in section 8.

Note: final preparation of **Biotin-Conjugate** (section 8.5) and **Streptavidin-HRP** (section 8.6) should occur immediately before use.

Assay Step		Details
1.	Wash	Remove the pre-coated plate from the sealed pouch, removed any un-needed strips and wash the plate as follows: a) Dispense 0.3 ml of 1x Wash Buffer into each well b) Aspirate the contents of each well c) Repeat step a and b
2.	Addition	Prepare Standard Curve as shown in section 8.4
3.	Addition	Add 100µl of Sample Diluent in duplicate to the blank wells
4.	Addition	Add 50µl of Sample Diluent to the sample wells
5.	Addition	Add 50µl of each sample in duplicate to the designated wells
6.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for 2 hours on a microplate shaker. (Shaking is absolutely necessary for an optimal test performance)
7.	Wash	Remove the cover and wash the plate as follows: a) Aspirate the liquid from each well b) Dispense 0.3 ml of 1x Wash Buffer into each well c) Aspirate the contents of each well d) Repeat step b and c another two times
8.	Addition	Add 100µl of diluted Biotin-Conjugate to all wells including blanks
9.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for 1 hour on a microplate shaker. (Shaking is absolutely necessary for an optimal test performance)
10.	Wash	Repeat wash step 7.
11.	Addition	Add 100µl of diluted Streptavidin-HRP solution into all wells
12.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for 1 hour on a microplate shaker. (Shaking is absolutely necessary for an optimal test performance)
13.	Wash	Repeat wash step 7.
14.	Addition	Add 100µl of ready-to-use Substrate Solution into all wells
15.	Incubation	Incubate for 20-30 minutes* at room temperature. Avoid direct exposure to light by wrapping the plate in aluminium foil
16.	Addition	Add 100µl of Stop Solution into all wells
<p>Read the absorbance value of each well (immediately after step 16.) on a spectrophotometer using 450 nm as the primary wavelength and optionally 630 nm as the reference wave length (610 nm to 650 nm is acceptable).</p>		

**Incubation time of the substrate solution is usually determined by the ELISA reader performance. Many ELISA readers only record absorbance up to 2.0 O.D. Therefore the colour development within individual microwells must be observed by the analyst, and the substrate reaction stopped before positive wells are no longer within recordable range*

10. Data Analysis


Calculate the average absorbance values for each set of duplicate standards, controls and samples. Ideally duplicates should be within 20% of the mean.

Generate a linear standard curve by plotting the average absorbance of each standard on the vertical axis versus the corresponding VEGF-A Standard concentration on the horizontal axis.

The amount of VEGF-A in each sample is determined by extrapolating OD values against VEGF-A standard concentrations using the standard curve.

Example VEGF-A Standard curve

Standard	human VEGF-A Conc	OD (450nm) mean	CV (%)
1	1000	2.254	2.4
2	500	1.286	3.2
3	250	0.771	0.6
4	125	0.419	2.5
5	62.5	0.258	0.1
6	31.3	0.163	0.3
Zero	0	0.069	-



Note: curve shown above should not be used to determine results. Every laboratory must produce a standard curve for each set of microwell strips assayed.

For samples human serum or plasmas which have been diluted 1:2 according to the protocol, the calculated concentration should be multiplied by the dilution factor (x2).

11. Assay limitations

Do not extrapolate the standard curve beyond the maximum standard curve point. The dose-response is non-linear in this region and good accuracy is difficult to obtain. Concentrated samples above the maximum standard concentration must be diluted with Sample Diluent or with your own sample buffer to produce an OD value within the range of the standard curve. Following analysis of such samples always multiply results by the appropriate dilution factor to produce actual final concentration.

The influence of various drugs on end results has not been investigated. Bacterial or fungal contamination and laboratory cross-contamination may also cause irregular results.

Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Completely empty wells before dispensing fresh Washing Buffer, fill with Washing Buffer as indicated for each wash cycle and do not allow wells to sit uncovered or dry for extended periods.

Disposable pipette tips, flasks or glassware are preferred, reusable glassware must be washed and thoroughly rinsed of all detergents before use.

As with most biological assays conditions may vary from assay to assay therefore **a fresh standard curve must be prepared and run for every assay.**

12. Performance Characteristics

12.1. Sensitivity

The limit of detection of human VEGF-A defined as the analyte concentration resulting in an absorption significantly higher than that of the dilution medium (mean plus two standard deviations) was determined to be 7.9 pg/ml (mean of 6 independent assays).

12.2. Specificity

The assay detects both natural and recombinant human VEGF-A. Cross-reactivity and interference of circulating factors of the immune system were evaluated by spiking these proteins at physiologically relevant concentrations into a human VEGF-A positive serum. No cross-reactivity was detected, notably with VEGF-B, VEGF-C, VEGF-D and PfGF.

Interference was detected for VEGF-R1 at concentrations > 200 pg/ml, and not for VEGF-R2.

12.3. Precision

Intra-assay

Reproducibility within the assay was evaluated in three independent experiments. Each assay was carried out with 6 replicates of 8 serum samples containing different concentrations of VEGF-A.

The calculated overall coefficient of variation was 6.2%.

Inter-assay

Assay to assay reproducibility within one laboratory was evaluated in three independent experiments. Each assay was carried out with 6 replicates of 8 serum samples containing different concentrations of VEGF-A:

The calculated overall coefficient of variation was 4.3%.

12.4. Dilution Parallelism

Serum, plasma and cell culture supernatant samples with different levels of human VEGF-A were analysed at serial 2 fold dilutions with 4 replicates each.

Sample matrix	Recovery of Exp. Val.	
	Range (%)	Mean (%)
Serum	74-104	90
Plasma (EDTA)	93-147	110
Plasma (citrate)	83-99	90
Plasma (heparin)	98-119	108
Cell culture supernatant	72-103	91

12.5. Spike Recovery

The spike recovery was evaluated by spiking 3 levels of human VEGF-A into serum, plasma and cells culture supernatant. Recoveries were determined with 4 replicates each. The amount of endogenous human VEGF-A in unspiked samples was subtracted from the spike values.

Sample matrix	Spike high (%)	Spike medium (%)	Spike low (%)
Serum	88	85	81
Plasma (EDTA)	77	77	79
Plasma (citrate)	92	90	94
Plasma (heparin)	106	88	64
Cell culture supernatant	98	92	88

12.6. Stability

Storage Stability

Aliquots of serum samples (spiked or unspiked) were stored at -20°C, 2-8°C, room temperature (RT) and at 37°C, and the human VEGF-A level determined after 24 h. There was no significant loss of human VEGF-A immunoreactivity detected during storage at -20°C and 2-8°C.

A significant loss of human VEGF-A immunoreactivity was detected during storage at RT and 37°C after 24 hours.

Freeze-thaw Stability

Aliquots of serum samples (spiked or unspiked) were stored frozen at -20°C and thawed up to 5 times, and the human VEGF-A levels determined. A significant decrease of human VEGF-A immunoreactivity was detected. Therefore samples should be stored in aliquots at -20°C and thawed only once.

12.7. Expected serum values

Donors (males and females) was tested for VEGF-A. The normal levels measured may vary with the sample collective used. (nd= non detectable, measured below the sensitivity).

Sample Matrix	Number of samples evaluated	Range (pg/ml)	% detectable	Mean of detectable (pg/ml)
Serum	40	nd-42.6	2.5	--
Plasma (EDTA)	40	nd-128.9	7.5	45.7
Plasma (citrate)	40	nd- 66.2	7.5	47.3
Plasma (Heparin)	40	nd- 311.4	7.5	144.3

13. Bibliography

1. Risau W, Nature. 1997 Apr 17;386(6626):671-4.
2. Ferrara N, Curr Top Microbiol Immunol. 1999;237:1-30.
3. Senger DR et al, Science. 1983 Feb 25;219(4587):983-5.
4. Careliet P et al, Curr Top Microbiol Immunol. 1999;237:133-58.
5. Norrby K, APMIS. 1997 Jun;105(6):417-37.
6. Arbiser JL et al, Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):861-6.
7. Gasparini F et al, J Natl Cancer Inst. 1997 Jan 15;89(2):139-47.
8. Toi M et al, Int J Oncol. 1999 Dec;15(6):1169-75.
9. Banks RE et al, Br J Cancer. 1998 Mar;77(6):956-64.
10. Plate KH et al, Nature. 1992 Oct 29;359(6398):845-8.
11. Weindel K et al, Neurosurgery. 1994 Sep;35(3):439-48.
12. Pinedo HM et al, Lancet. 1998 Nov 28;352(9142):1775-7.
13. O'Byrne KJ et al, Lancet. 1999 353:1493-
14. Salgado R et al, Br J Cancer. 1999 May;80(5-6):892-7.
15. Koch AE et al, J Immunol. 1994 Apr 15;152(8):4149-56.
16. Neulen J et al, J Clin Endocrinol Metab. 1995 Jun;80(6):1967-71.
17. Ferrara N et al, Nat Med. 1998 Mar;4(3):336-40.
18. Millauer Bet al, Cancer Res. 1996 Apr 1;56(7):1615-20.
19. Witte L et al, Cancer Metastasis Rev. 1998 Jun;17(2):155-61.
20. McMahon G, Oncologist. 2000;5 Suppl 1:3-10.

14. Assay Summary

Total procedure length : 4h30min

Add Standard Curve and Sample



Incubate 2 hours at room temperature



Wash three times



Add 100µl of diluted Biotin-Conjugate



Incubate 1 hour at room temperature



Wash three times



Add 100µl of diluted Streptavidin-HRP



Incubate 1 hour at room temperature



Wash three times



Add 100µl of Substrate Solution

Protect from light. Let the color develop for 20-30 min.



Add 100µl Stop Solution



Read Absorbance at 450 nm

Supplier:

Diaclone SAS
6 Rue Docteur Girod
25020 Besançon Cedex
France
Tel +33 (0)3 81 41 38 38
Fax +33 (0)3 81 41 36 36
Email: info@diacclone.com